Literature DB >> 27603912

Engineered Breast Cancer Cell Spheroids Reproduce Biologic Properties of Solid Tumors.

Stephanie L Ham1, Ramila Joshi1, Gary D Luker2, Hossein Tavana1.   

Abstract

Solid tumors develop as 3D tissue constructs. As tumors grow larger, spatial gradients of nutrients and oxygen and inadequate diffusive supply to cells distant from vasculature develops. Hypoxia initiates signaling and transcriptional alterations to promote survival of cancer cells and generation of cancer stem cells (CSCs) that have self-renewal and tumor-initiation capabilities. Both hypoxia and CSCs are associated with resistance to therapies and tumor relapse. This study demonstrates that 3D cancer cell models, known as tumor spheroids, generated with a polymeric aqueous two-phase system (ATPS) technology capture these important biological processes. Similar to solid tumors, spheroids of triple negative breast cancer cells deposit major extracellular matrix proteins. The molecular analysis establishes presence of hypoxic cells in the core region and expression of CSC gene and protein markers including CD24, CD133, and Nanog. Importantly, these spheroids resist treatment with chemotherapy drugs. A combination treatment approach using a hypoxia-activated prodrug, TH-302, and a chemotherapy drug, doxorubicin, successfully targets drug resistant spheroids. This study demonstrates that ATPS spheroids recapitulate important biological and functional properties of solid tumors and provide a unique model for studies in cancer research.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  aqueous two-phase systems; cancer stem cells; drug resistance; hypoxia; spheroids

Mesh:

Substances:

Year:  2016        PMID: 27603912      PMCID: PMC5142748          DOI: 10.1002/adhm.201600644

Source DB:  PubMed          Journal:  Adv Healthc Mater        ISSN: 2192-2640            Impact factor:   9.933


  88 in total

Review 1.  Exploiting tumour hypoxia in cancer treatment.

Authors:  J Martin Brown; William R Wilson
Journal:  Nat Rev Cancer       Date:  2004-06       Impact factor: 60.716

2.  The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer.

Authors:  Nilgün Kapucuoğlu; Kemal Kürşat Bozkurt; Şirin Başpınar; Murat Koçer; Hasan Erol Eroğlu; Raşit Akdeniz; Mehtap Akçil
Journal:  Pathol Res Pract       Date:  2015-06-01       Impact factor: 3.250

3.  Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

Authors:  Sant P Chawla; Lee D Cranmer; Brian A Van Tine; Damon R Reed; Scott H Okuno; James E Butrynski; Douglas R Adkins; Andrew E Hendifar; Stew Kroll; Kristen N Ganjoo
Journal:  J Clin Oncol       Date:  2014-09-02       Impact factor: 44.544

4.  Clinicopathologic correlation of cancer stem cell markers CD44, CD24, VEGF and HIF-1α in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.

Authors:  Zhen Wang; Qin Shi; Zemin Wang; Yongping Gu; Yueping Shen; Maoming Sun; Min Deng; Hua Zhang; Junchu Fang; Shuying Zhang; Fang Xie
Journal:  Pathol Res Pract       Date:  2011-07-28       Impact factor: 3.250

5.  TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging.

Authors:  Sarah G J A Peeters; Catharina M L Zegers; Rianne Biemans; Natasja G Lieuwes; Ruud G P M van Stiphout; Ala Yaromina; Jessica D Sun; Charles P Hart; Albert D Windhorst; Wouter van Elmpt; Ludwig J Dubois; Philippe Lambin
Journal:  Clin Cancer Res       Date:  2015-03-24       Impact factor: 12.531

6.  CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy.

Authors:  A Kathleen McClendon; Jeffry L Dean; Dayana B Rivadeneira; Justine E Yu; Christopher A Reed; Erhe Gao; John L Farber; Thomas Force; Walter J Koch; Erik S Knudsen
Journal:  Cell Cycle       Date:  2012-07-15       Impact factor: 4.534

7.  Hypoxia attenuates the p53 response to cellular damage.

Authors:  Marcus Achison; Ted R Hupp
Journal:  Oncogene       Date:  2003-05-29       Impact factor: 9.867

Review 8.  Relapsed triple-negative breast cancer: challenges and treatment strategies.

Authors:  Valentina Guarneri; Maria Vittoria Dieci; Pierfranco Conte
Journal:  Drugs       Date:  2013-08       Impact factor: 9.546

9.  HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma.

Authors:  Y J Liu; D Shen; X Yin; P Gavine; T Zhang; X Su; P Zhan; Y Xu; J Lv; J Qian; C Liu; Y Sun; Z Qian; J Zhang; Y Gu; X Ni
Journal:  Br J Cancer       Date:  2014-02-11       Impact factor: 7.640

10.  Carbonic anhydrase 9 is associated with chemosensitivity and prognosis in breast cancer patients treated with taxane and anthracycline.

Authors:  Naoki Aomatsu; Masakazu Yashiro; Shinichiro Kashiwagi; Hidemi Kawajiri; Tsutomu Takashima; Masahiko Ohsawa; Kenichi Wakasa; Kosei Hirakawa
Journal:  BMC Cancer       Date:  2014-06-04       Impact factor: 4.430

View more
  17 in total

Review 1.  Tumour-on-a-chip: microfluidic models of tumour morphology, growth and microenvironment.

Authors:  Hsieh-Fu Tsai; Alen Trubelja; Amy Q Shen; Gang Bao
Journal:  J R Soc Interface       Date:  2017-06       Impact factor: 4.118

Review 2.  Biomaterials-Based Approaches to Tumor Spheroid and Organoid Modeling.

Authors:  Pradip Shahi Thakuri; Chun Liu; Gary D Luker; Hossein Tavana
Journal:  Adv Healthc Mater       Date:  2017-12-04       Impact factor: 9.933

Review 3.  Three-dimensional models of breast cancer-fibroblasts interactions.

Authors:  Sunil Singh; Sydnie Tran; Justin Putman; Hossein Tavana
Journal:  Exp Biol Med (Maywood)       Date:  2020-04-10

4.  Comparative Study of Multicellular Tumor Spheroid Formation Methods and Implications for Drug Screening.

Authors:  Maria F Gencoglu; Lauren E Barney; Christopher L Hall; Elizabeth A Brooks; Alyssa D Schwartz; Daniel C Corbett; Kelly R Stevens; Shelly R Peyton
Journal:  ACS Biomater Sci Eng       Date:  2017-03-13

5.  Three dimensional engineered models to study hypoxia biology in breast cancer.

Authors:  Vaishali Aggarwal; Oshin Miranda; Paul A Johnston; Shilpa Sant
Journal:  Cancer Lett       Date:  2020-06-20       Impact factor: 8.679

6.  Modeling Adaptive Resistance of KRAS Mutant Colorectal Cancer to MAPK Pathway Inhibitors with a Three-Dimensional Tumor Model.

Authors:  Pradip Shahi Thakuri; Astha Lamichhane; Sunil Singh; Megha Gupta; Gary D Luker; Hossein Tavana
Journal:  ACS Pharmacol Transl Sci       Date:  2020-10-09

7.  Quantitative Size-Based Analysis of Tumor Spheroids and Responses to Therapeutics.

Authors:  Pradip Shahi Thakuri; Megha Gupta; Madison Plaster; Hossein Tavana
Journal:  Assay Drug Dev Technol       Date:  2019-04       Impact factor: 1.738

Review 8.  Microfluidic Biosensor-Based Devices for Rapid Diagnosis and Effective Anti-cancer Therapeutic Monitoring for Breast Cancer Metastasis.

Authors:  V S Sukanya; Subha Narayan Rath
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 9.  Breast cancer models: Engineering the tumor microenvironment.

Authors:  Gokhan Bahcecioglu; Gozde Basara; Bradley W Ellis; Xiang Ren; Pinar Zorlutuna
Journal:  Acta Biomater       Date:  2020-02-09       Impact factor: 8.947

Review 10.  Modeling adaptive drug resistance of colorectal cancer and therapeutic interventions with tumor spheroids.

Authors:  Astha Lamichhane; Pradip Shahi Thakuri; Pouria Rafsanjani Nejad; Hossein Tavana
Journal:  Exp Biol Med (Maywood)       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.